Very good news that the "new" data of two of these trials warranted 'PODIUM PRESENTATIONS". Presenting at the podium is a competitive endeavour, so the new data should remain very positive, otherwise they wouldn't bother.
2 March 2017, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the company will present new clinical data from three combination studies of CAVATAK®, its novel investigational cancer immunotherapy, and checkpoint inhibitor drugs at the American Association for Cancer Research (AACR) Annual Meeting 2017, which will be held in Washington DC from April 1 to 5. Details of the two podium presentations in a clinical trials plenary session and one poster presentation follow.
Very good news that the "new" data of two of these trials...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)